- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02565524
the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder. (GenAuDiss)
Exploration and Characterization of the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder and Their First-degree Relatives (GenAuDiss).
Early onset schizophrenia "early dissociative disorder" is a rare disorder with a low incidence of approximately (1/5000 to 1/20000). Its link with autism spectrum disorders remains unknown although both are serious neurodevelopmental diseases. As part of the 2011-2013 Interregional hospital Clinical Research program, University Department of Child and Adolescent Psychiatry Pediatric Hospitals of CHU de Nice Lenval identified patients with a complex phenotype characterized by an early schizophrenia associated with autism spectrum disorders and developmental disabilities in mild to moderate. This phenotype could be a new syndrome.
The goal of our project is to define the genetic causes of this phenotype. The technique of high throughput sequencing will be used to obtain the sequence of exomes of these patients and their families. This study will therefore be important to give an accurate diagnosis for patients and their families. Moreover, we believe that this project will identify new genes involved allowing a better understanding of the pathophysiology. Recent studies show the involvement of mutations in several genes (eg NRXN1 and UPF3B) in these different clinical phenotypes. However, the genetic basis of the childhood and early onset schizophrenia are much less well known than those of autism spectrum disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction: Early-onset Schizophrenia (EOS) is a rare and severe condition displaying early dissociative disorder (i.e., age of onset < 18 years). A higher rate of neurodevelopmental abnormalities is observed in EOS compared to adult onset schizophrenia (AOS). Thus, patients affected by EOS typically present intellectual, learning, communication or neuromotor impairments, as well as attention deficit hyperactivity disorder. Early signs of autism spectrum disorders (ASD) are also found in 30% of patients with EOS.
Cytogenetics abnormalities, including copy number variations (CNVs), are frequent in neurodevelopmental disorders and have been linked to ASD physiopathology. Implicated genes encode proteins playing a role in brain development, synaptic morphology, plasticity and neurogenesis. In addition, an increasing number of genetic abnormalities are shared by EOS and ASD, suggesting that schizophrenia can be considered a neurodevelopmental disorder.
The main objective of the present study is to identify mutations in genes involved in neurodevelopmental pathways in our cohort of patients affected by both EOS and ASD.
Method and analysis: We describe here a multicenter study in a pediatric population named "Exploration and characterization of genetic and phenotypic profile of the 'early dissociative disorder' associated with autism spectrum disorder (GenAuDiss)". The study started in April 2014. The inclusion criteria are: age 7 to 22 years, diagnoses of EOS with co-morbid ASD and IQ > 50; as well as parents and siblings of the included patients.
We perform standardized psychiatric assessments (MINI, K-SADS-PL, PANSS, SANS, TCI 226, and AQ) and neurocognitive evaluations (IQ, TMT A/B, and verbal fluency). Then, we study variants of the coding part of the DNA (exome), using next generation sequencing (NGS) process on trio (mother, father, and child). Divers bio-informatics tools such as RVIS and PolyPhen-2 will be used to prioritize the potential candidate genes. The inclusion period of this study will end in November 2019.
Ethics and dissemination: The study protocol was approved by the Ethics Committee 'Sud Méditerrané V' (number 14.002) and by the French National Agency for Medicines and Health Products Safety (ANSM 2013-A01699-36). All patients, their parents and siblings signed informed consent upon enrolment in the study.
Results of the present study should help to unravel the molecular pathology of EOS, paving the way for an early therapeutic intervention
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nice, France, 06200
- Fondation Lenval
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Of the child:
- ≥ 7 years, <18 (below 7 years the diagnosis of schizophrenia is not possible)
- Schizophrenia Diagnosis done using the diagnostic tool Kiddie sads
- Autism Diagnosis done using the diagnostic scale Autism Diagnostic interview (ADI-R)
- Intelligence quotient (IQ) ≥ 50 at Wechsler Intelligence Scale for Children (WISC) IV abridged version
- Clinical examination
- Affiliation to social security
- Obtaining the authorization of the holders of parental authority
Brothers and sisters:
- Minor or Major
- Similarly biological parents
- Clinical examination
- Affiliation to social security
- Obtaining the authorization of the holders of parental authority for minors or informed consent for major
Parents:
- Biological Parent
- Clinical examination
- Affiliation to social security
- Informed Consent
Exclusion Criteria:
Of the child:
- Children refusing to participate
- Children without verbal language
Brothers and sisters:
- Children refusing to participate
- Adults protected by law
Parents:
- Refusing to participate
- Adults are protected by law
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: genetic and phenotypic profile
blood sample, clinical and neurocognitive assessment
|
Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing standard karyotype
Time Frame: inclusion visit
|
A standard karyotype at a resolution of 300 to 400 bands per haploid lot. It can diagnose numerical anomalies and certain structural abnormalities such as reciprocal translocations, inversions, deletions. A standard karyotype at a resolution of 300 to 400 bands per haploid lot is established initially. It can diagnose numerical anomalies and certain structural abnormalities such as reciprocal translocations, inversions, deletions Big. The pathological nature of these mutations will be stutied on the gene function and reaches its pattern of expression. |
inclusion visit
|
characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing search CGG
Time Frame: inclusion visit
|
A search of the CGG expansion hypermethylated in the 5 'UTR of the FMR1 gene mutation that causes Fragile X syndrome.
|
inclusion visit
|
characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing whole exome sequencing
Time Frame: inclusion visit
|
Whole Exome Sequencing on trio (mother, father and child); This technology has demonstrated its power in recent years to determine the genetic causes of many rare diseases (Ropers, HH., 2012).
|
inclusion visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intensity of positive symptoms of schizophrenia
Time Frame: inclusion visit
|
Evaluation of the intensity of positive and negative symptoms, general psychopathology and subtypes of schizophrenia by using positive and negative syndrome scale (PANSS)
|
inclusion visit
|
Co-morbid psychiatric diagnosis
Time Frame: inclusion visit
|
Evaluation of clinical profile: by using K-SADS-PL scale for DSM IV-TR / DSM-5 co-morbid psychiatric diagnosis of patients and minor siblings and by using MINI assessments for DSM IV-TR / DSM 5 psychiatric diagnosis of parents and major siblings.
|
inclusion visit
|
Evaluation of executive and attentional by the verbal fluency test
Time Frame: inclusion visit
|
Evaluation of executive and attentional functions of patients using Trail Making Test (TMT) A and B and verbal fluency;
|
inclusion visit
|
Clinical evaluation of autistic symptoms
Time Frame: inclusion visit
|
Clinical evaluation of autistic symptoms by using AQ (Baron-Cohen) in siblings and parents
|
inclusion visit
|
Neurocognitive profile
Time Frame: inclusion visit
|
Evaluation of cognitive functioning by Wechsler Intelligence Scale for Children Scale IV (WISC IV).full version in patient and WISC IV abridged version in minor siblings; Wechsler Adult Intelligence Scale-III (WAIS III) in a short form in adult siblings and parents
|
inclusion visit
|
Personality dimensional test
Time Frame: inclusion visit
|
Personality dimensional test using computerized version of TCI 226 (Cloninger) in parents
|
inclusion visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emmanuelle DOR, MD, Fondation Lenval
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-HPNCL08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on genetic and phenotypic profile
-
Kyowa Kirin Co., Ltd.CompletedHealthy Men and Subjects With Ulcerative ColitisJapan
-
Bien-Willner Physicians Group PANo One Left Alone; Carolina Blood and Cancer Care AssociatesNot yet recruitingAdvanced Cancer | Myeloid Malignancy | Solid Tumor, AdultUnited States
-
Zhejiang Cancer HospitalUnknownNon-small Cell Lung Cancer | Aquired Resistance | EGFR TKIsChina
-
University of ChicagoRecruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Breast Carcinoma | Lung Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Puerto Rico
-
Gaffree & Guinle Universitary HospitalCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional...RecruitingDegenerative Disc Disease | Back Pain, LowBrazil
-
Hospital Universitario Mayor MederiUniversidad del RosarioNot yet recruitingAntibiotic Resistant Strain | Biliary Infection
-
PharmaNest, IncIcahn School of Medicine at Mount Sinai; Chinese University of Hong Kong; Imperial... and other collaboratorsNot yet recruitingMetabolic Dysfunction-associated Steatotic Liver DiseaseUnited States, Hong Kong, United Kingdom, Spain